ევროპის რესპირაციული საზოგადოების ყოველწლიური კონგრესი

  • Published on
    26-Jan-2016

  • View
    44

  • Download
    7

DESCRIPTION

. 18-22 2010 nana qiria , samSabaToba , 05.10.10. . - PowerPoint PPT Presentation

Transcript

  • 18-22 2010

    nana qiria, samSabaToba, 05.10.10

  • : , , , (160);: 1 621537: 101,4 : 4 200 000: 803

  • Fira de EuropaHall 1 Hall 2 Hall3Amsterdam StockholmGeneva Nice Glasgow BrusselsMadrid CopenhagenFlorence Izmir Budapest Bucharest

  • (XX) (18-22 ) , , , ..) -486; (18.09.10) 23, 1 6554

  • ERS,BARCELONA 2010Multidrug-resistant and extensively drug resistant tuberculosisG. Sotgiu, R. Centis, L. DAmbrosio, S. De Lorenzo, M. D. Richardson, A. Facchini, C. Lange, D. Manissero, G. B. Migliori, TBNET Tubeculosis Network European Trialsgroup (Sassari, Tradate, Sondalo, Italy; Seattle, United States Of America; , Germany; Stockholm, Sweden) Development of a standardized tool to survey MDR-/XDR-TB case management in Europe ;A. Facchini, L. DAmbrosio, G. Sotgiu, G. Guenther, J. P. Zellweger, G. Bothamley, R. Centis, R. Muetterlein, S. De Lorenzo, M. Villar, K. Kliiman, V. Spinu, C. Lange, D. Manissero, G. B. Migliori, TBNET Tuberculosis Network European Trialsgroup (Tradate, Sassari, Sondalo, Italy; , Germany; Berne, Switzerland; London, United Kingdom; Lisbon, Portugal; Tartu, Estonia; Bucharest, Romania; Stockholm, Sweden) Is management of MDR-/XDR-TB in Europe adequate? A TBNET survey

  • ERS,BARCELONA 2010Multidrug-resistant and extensively drug resistant tuberculosisV. Crudu, S. Ruch-Gerdes, S. Niemann, N. Moraru, L. Carchilan, V. Lesan, G. Blagodeteleva, E. Stratan (Chisinau, Republic Of Moldova; Borstel, Germany Poor infection control increase risk of reinfection with MDR or XDR-TB strains ;A. Skrahina, V. Solodovnikova, A. Astrauko, A. Skrahin, H. Hurevich, L. Surkova (Minsk, Belarus) Extensively drug-resistant tuberculosis (XDR-TB) treatment outcome. Cohort studyA. Nodieva, I. Pole, L. Cesniece, V. Riekstina, A. Kosevacka, Z. Konosenoka, A. Toma, V. Skripconoka, G. Skenders, V. Zvigure, A. Lipska, I. Bruse, R. Deklava, I. Gravite, I. Leskevica, P. Moonan, K. Ijaz, V. Leimane, T. Holtz (Riga, Latvia; Atlanta, United States Of America) Epidemiological links and laboratory contamination among clustered TB cases in Riga City and district

  • ERS,BARCELONA 2010Multidrug-resistant and extensively drug resistant tuberculosisK. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom) Adverse drug reactions in South African patients being treated for XDR-TB ;E. Nosova, A. Bukatina, K. Galkina, M. Krasnova (Moscow, Russian Federation) Diagnosis of Mycobacterium tuberculosis drug resistance using molecular genetic methods

  • ERS,BARCELONA 2010

    G. Sotgiu, R. Centis, L. DAmbrosio, S. De Lorenzo, M. D. Richardson, A. Facchini, C. Lange, D. Manissero, G. B. Migliori, TBNET Tubeculosis Network European Trialsgroup (Sassari, Tradate, Sondalo, Italy; Seattle, United States Of America; , Germany; Stockholm, Sweden) Development of a standardized tool to survey MDR-/XDR-TB case management in Europe ;

  • , M(X)DR/TB : 2 . ( , ) ; { () }.

  • ERS,BARCELONA 2010A. Facchini, L. DAmbrosio, G. Sotgiu, G. Guenther, J. P. Zellweger, G. Bothamley, R. Centis, R. Muetterlein, S. De Lorenzo, M. Villar, K. Kliiman, V. Spinu, C. Lange, D. Manissero, G. B. Migliori, TBNET Tuberculosis Network European Trialsgroup (Tradate, Sassari, Sondalo, Italy; , Germany; Berne, Switzerland; London, United Kingdom; Lisbon, Portugal; Tartu, Estonia; Bucharest, Romania; Stockholm, Sweden) Is management of MDR-/XDR-TB in Europe adequate? A TBNET survey

  • Is management of MDR-/XDR-TB in Europe adequate? A TBNET survey , 3 ; MDR- 120 (40-40 ) 3 ; XDR-TB -12 (10%), MDR-TB - 73 (60.8%) 35 (29.2%) [ M (X)DR-TB]. (87/120, 73,3%); 41 (_+16)

  • Is management of MDR-/XDR-TB in Europe adequate? A TBNET survey : -38(31,7%), -2(1,7%), - 8 (6,7%), -7(5,8%), -1 (0,8%), 64 (53,3%) . - 28,3%(32/120); 12,5% (15/120); ( , , ) (80/120, 66,7%).: , , .

  • V. Crudu, S. Ruch-Gerdes, S. Niemann, N. Moraru, L. Carchilan, V. Lesan, G. Blagodeteleva, E. Stratan (Chisinau, Republic Of Moldova; Borstel, Germany Poor infection control increase risk of reinfection with MDR or XDR-TB strains : M(X)DR/TB- : (17/26) , 5 , 4 2 (H , Sm); 2-3 13 MDR ,

    , M(X)DR TB .

  • Extensively drug-resistant tuberculosis (XDR-TB) treatment outcome. Cohort study A. Skrahina, V. Solodovnikova, A. Astrauko, A. Skrahin, H. Hurevich, L. Surkova (Minsk, Belarus):XDR-TB 49 XDR-TB 2004-2009 : 49 27(55%) ( 23-47% ), 9 (18%) - , 7(14%) , 6(12%) - ;( 3 , 2-,1- ) , .XDR-TB- . , -2 XDR-TB .

  • A. Nodieva, I. Pole, L. Cesniece, V. Riekstina, A. Kosevacka, Z. Konosenoka, A. Toma, V. Skripconoka, G. Skenders, V. Zvigure, A. Lipska, I. Bruse, R. Deklava, I. Gravite, I. Leskevica, P. Moonan, K. Ijaz, V. Leimane, T. Holtz (Riga, Latvia; Atlanta, United States Of America) Epidemiological links and laboratory contamination among clustered TB cases in Riga City and district

    649 , 299 (46%) 60 . , 97 (17 , 6 ), .

  • .

    DST S 6 ( ) DR 1 , ( ) MDR 2 , , - S 11 DR 1 , , .MDR 3

  • Epidemiological links and laboratory contamination among clustered TB cases in Riga City and district

    , .

  • Adverse drug reactions in South African patients being treated for XDR-TB K. Shean, M. Badri, G. Symons, E. Pietersen, L. Page-Shipp, A. Burns, P. Baitiswe, M. Grobusch, P. Willcox, A. Zumla, K. Dheda (Cape Town, Johannesburg, Kimberley, South Africa; , United Kingdom) 115 XDR-TB , 2002-2008 3 .

    () 58% (67/115) 161 : 58/161 (36%) , 69/161 (435) , 23/161(16%) , 2/161 (1,2%) , 6(3,7%) . , - . 115- 48(42%) - - , - . .

  • Adverse drug reactions in South African patients being treated for XDR-TB

    XDR-TB , , . , . - .- .

  • Diagnosis of Mycobacterium tuberculosis drug resistance using molecular genetic methods E. Nosova, A. Bukatina, K. Galkina, M. Krasnova (Moscow, Russian Federation)

    Bactec MGIT 960 (Becton Dickinson) 2 -: TB-Biochip TB-Biochip-2 (Biochip-IMB, Russia)- 301 ; Lowenstein-Jensen- . , 11.2% MDR . 3,4% . MDR 84.8%, 56.5% FQ, XDR TB 6 . ., , , , .

Recommended

View more >